Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Alaunos Therapeutics
About
Alaunos Therapeutics is a biotechnology company that acquires, develops, and commercializes cancer therapies.
- New York,New York,United States
- 101 - 250
- https://alaunos.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $15.70M
- Industries
- Biotechnology,Genetics,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:ZIOP
- Legal Name
- Ziopharm Oncology, Inc.
- Also Known As
- Ziopharm Oncology
Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 29, 2022 | Post-IPO Equity | $15.70M | — | — | — | Detail |
| Sep 13, 2019 | Post-IPO Equity | $8.40M | — | — | — | Detail |
| Jul 7, 2016 | Post-IPO Equity | $120M | — | — | — | Detail |
| Jan 28, 2015 | Post-IPO Equity | $57.50M | — | — | — | Detail |
| Nov 2, 2010 | Grant | $733K | — | — | — | Detail |
Investors
Employee Profiles
